IRIS
GEMMA, SANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.356
EU - Europa 9.221
AS - Asia 1.626
AF - Africa 51
SA - Sud America 22
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 12
Totale 20.305
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.299
GB - Regno Unito 2.647
IT - Italia 1.535
IE - Irlanda 1.461
CN - Cina 1.045
SE - Svezia 754
RU - Federazione Russa 677
UA - Ucraina 644
DE - Germania 590
FR - Francia 376
SG - Singapore 275
FI - Finlandia 241
TR - Turchia 142
ES - Italia 68
CA - Canada 53
CZ - Repubblica Ceca 46
CI - Costa d'Avorio 37
AT - Austria 35
IN - India 34
BE - Belgio 33
IR - Iran 28
GR - Grecia 23
VN - Vietnam 20
NL - Olanda 19
AU - Australia 15
EU - Europa 11
JP - Giappone 11
PL - Polonia 11
PT - Portogallo 11
RO - Romania 10
EG - Egitto 7
SA - Arabia Saudita 7
BR - Brasile 6
CL - Cile 6
ID - Indonesia 6
LV - Lettonia 6
BD - Bangladesh 5
BG - Bulgaria 5
KR - Corea 5
PK - Pakistan 5
AZ - Azerbaigian 4
CH - Svizzera 4
HK - Hong Kong 4
HU - Ungheria 4
IL - Israele 4
MY - Malesia 4
RS - Serbia 4
AE - Emirati Arabi Uniti 3
DK - Danimarca 3
KW - Kuwait 3
MA - Marocco 3
PA - Panama 3
PE - Perù 3
AL - Albania 2
AR - Argentina 2
BO - Bolivia 2
HR - Croazia 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LT - Lituania 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
TW - Taiwan 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BY - Bielorussia 1
CO - Colombia 1
EC - Ecuador 1
EE - Estonia 1
GE - Georgia 1
IM - Isola di Man 1
IQ - Iraq 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
MC - Monaco 1
NG - Nigeria 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 20.305
Salva come PNG Salva come JPEG
Città #
Southend 2.462
Fairfield 1.553
Dublin 1.449
Ashburn 888
Chandler 732
Woodbridge 701
Siena 596
Wilmington 579
Seattle 570
Houston 547
Cambridge 541
Jacksonville 534
Ann Arbor 397
Princeton 251
Beijing 250
Singapore 224
Nanjing 198
Dearborn 145
Izmir 122
Fremont 118
New York 110
Florence 109
Helsinki 109
Boardman 99
Shanghai 94
San Mateo 74
San Diego 73
Washington 63
Moscow 59
Nanchang 59
Málaga 55
Lancaster 47
Milan 45
Rome 45
Hebei 42
Brno 40
Shenyang 39
Abidjan 37
Lappeenranta 37
Jiaxing 36
Aachen 34
Redwood City 33
Venezia 33
Kunming 32
Brussels 31
London 30
Los Angeles 30
Norwalk 30
Düsseldorf 29
Jinan 29
Vienna 28
Menlo Park 26
Munich 26
Ottawa 25
Tianjin 25
Guangzhou 24
Ningbo 23
Toronto 20
Changsha 19
Dong Ket 19
San Francisco 17
Turin 16
Hefei 15
Parma 15
Avellino 14
Hangzhou 14
Prato 14
Marietta 12
Pisa 12
Borgo San Lorenzo 11
Hanover 11
San Giovanni Valdarno 11
Zhengzhou 11
Columbus 10
Salerno 10
Fisciano 9
Frankfurt am Main 9
Maletto 9
Naples 9
Arezzo 8
Catanzaro 8
Dallas 8
Palermo 8
Taizhou 8
Ventimiglia 8
Bari 7
Bologna 7
Changchun 7
Padova 7
Palo Alto 7
Santa Clara 7
Tokyo 7
Catania 6
Lanzhou 6
Mestre 6
Philadelphia 6
Riga 6
Tegoleto 6
Zanjan 6
Albosaggia 5
Totale 15.048
Salva come PNG Salva come JPEG
Nome #
Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages 294
Development of novel cyclic peptides as pro-apoptotic agents 273
Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents 270
Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]- N -[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues 263
(S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: further exploration of bioisosteric replacements and structural and biological investigation 257
Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain 249
Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies 230
Synthetic spirocyclic endoperoxides: new antimalarial scaffolds 227
First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents 216
Bridged bicyclic 2,3-dioxabicyclo[3.3.1]nonanes as antiplasmodial agents: Synthesis, structure-activity relationships and studies on their biomimetic reaction with Fe(II) 215
Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain 213
Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems 212
Natural Compounds and Synthetic Drugs to Target FAAH Enzyme 212
Synthesis, Molecular Modelling and Biological Studies of 3-hydroxy-pyrane-4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors 211
Old but gold: tracking the new guise of Histone Deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases 211
Targeting Dopamine D3and Serotonin 5-HT1Aand 5-HT2AReceptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies 200
Identification of novel fluorescent probes preventing PrP(Sc) replication in prion diseases 199
A Jocic-type approach for a practical and scalable synthesis of pyrrolonaphthoxazepine (PNOX)-based potent proapoptotic agents 199
Activation of the Wnt pathway by small peptides: rational design, synthesis and biological evaluation 198
Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking 197
null 195
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine d3 and serotonin 5-HT 1A and 5-HT2A receptors: Design, synthesis, and effects on behavior 188
Structural characterization of Giardia duodenalis thioredoxin reductase (gTrxR) and computational analysis of its interaction with NBDHEX 186
Targeting clinically-relevant metallo-β-lactamases: from high-throughput docking to broad-spectrum inhibitors 185
Selective Kainate Receptor (GluK1) Ligands Structurally Based upon 1H-Cyclopentapyrimidin-2,4(1H,3H)-dione: Synthesis, Molecular Modeling, and Pharmacological and Biostructural Characterization 184
A stereoselective route to 6-substituted pyrrolo-1,5-benzoxazepinones and their analogues 183
Cinnamic acids derived compounds with antileishmanial activity target Leishmania amazonensis arginase 183
1H-Cyclopentapyrimidine-2,4(1H,3H)-dione-Related Ionotropic Glutamate Receptors Ligands. Structure-Activity Relationships and Identification of Potent and Selective iGluR5 Modulators 180
Optimization of 4-Aminoquinoline/Clotrimazole-Based Hybrid Antimalarials: Further Structure-Activity Relationships, in vivo Studies, and Preliminary Toxicity Profiling 178
Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease 174
Synthetic studies toward 1,2-dioxanes as precursors of potential endoperoxide-containing antimalarials 173
Telomerase-based cancer therapeutics: a review on their clinical trials 173
Discovery of Potent Inhibitors of Human and Mouse Fatty Acid Amide Hydrolases 171
Non-Nucleoside Inhibitors of Human Adenosine Kinase: Synthesis, Molecular Modeling, and Biological Studies 169
Pyrrolo 1,3 benzothiazepine-based Atypical Antipsychotic Agents. Synthesis, Structure-Activity Relationship, Molecular Modeling, and Biological Studies 169
A light in the dark: State of the art and perspectives in optogenetics and optopharmacology for restoring vision 169
Discovery of Bishomo(hetero)arylpiperazines as Novel Multifunctional Ligands Targeting Dopamine D-3 and Serotonin 5-HT1A and 5-HT2A Receptors 168
Synthesis and Antiplasmodial Activity of Bicyclic Dioxanes as Simplified Dihydroplakortin Analogues 166
Exploiting Protein Fluctuations at the Active-Site Gorge of Human Cholinesterases: Further Optimization of the Design Strategy to Develop Extremely Potent Inhibitors 165
Design and Synthesis of Potent Antimalarial Agents Based on Clotrimazole Scaffold: Exploring an Innovative Pharmacophore 165
Mimicking the Intramolecular Hydrogen Bond: Synthesis, Biological Evaluation, and Molecular Modeling of Benzoxazines and Quinazolines as Potential Antimalarial Agents 165
Synthesis and structure–activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds 165
Microwave-assisted synthesis of 4-quinolylhydrazines followed by nickel boride reduction: a convenient approach to 4-aminoquinolines and derivatives 164
A synthetic strategy to bridged 2,3,8-trioxabicyclo[3,3,1]nonane endoperoxides 164
Synthesis of Dihydroplakortin, 6-epi-Dihydroplakortin, and Their C10-Desethyl Analogues 163
The Interactions of the 5-HT3 Receptor with Quipazine-Like Arylpiperazine Ligands. The Journey Track at the End of the First Decade of the Third Millennium 162
A stereoselective approach to peptidomimetic BACE1 inhibitors 162
Quinolylhydrazones as novel inhibitors of Plasmodium falciparum serine protease PfSUB1 160
Synthetic studies toward bicyclic endoperoxides presenting polar side chains 160
Novel quinolone-based potent and selective HDAC6 inhibitors: synthesis, molecular modeling studies and biological investigation 159
Pyrroloquinoxaline Derivatives as High-Affinity and Selective 5-HT3 Receptor Agonists: Synthesis, Further Structure-Activity Relationships, and Biological Studies 157
ANTIMALARIAL AGENTS HAVING POLYAROMATIC STRUCTURE 157
Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases 156
Novel peptidomimetics as BACE-1 inhibitors: synthesis, molecular modeling, and biological studies 154
Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains 152
Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling 152
Development of Antitubercular Compounds Based on a 4-Quinolylhydrazone Scaffold. Further Structure-activity Relationship Studies 151
Design, synthesis, and structure-activity relationship studies of 4-quinolinyl- and 9-acrydinylhydrazones as potent antimalarial agents 151
Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability 151
Raising the bar in anticancer therapy: recent advances in, and perspectives on, telomerase inhibitors 150
A palladium-catalyzed synthetic approach to new Huperzine A analogues modified at the pyridone ring 148
Selective Fatty Acid Amide Hydrolase Inhibitors as Potential Novel Antiepileptic Agents 147
Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel, selective, and highly potent BuChE inhibitors 146
Malaria chemotherapy: recent advances in drug development 145
Multifunctional Cholinesterase and Amyloid Beta Fibrillization Modulators. Synthesis and Biological Investigation 143
Pyrroloquinoxaline hydrazones as fluorescent probes for amyloid fibrils 142
Harnessing the role of HDAC6 in Idiopathic Pulmonary Fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors 142
Pyrrolo[1,5]benzoxa(thia)zepines as a New Class of Potent Apoptotic Agents. Biological Studies and Identification of an Intracellular Location of Their Drug Target 141
Specific Targeting of Hepatitis C Virus NS3 RNA Helicase. Discovery of the Potent and Selective Competitive Nucleotide-Mimicking Inhibitor QU663 141
Discovery of Huperzine A/Tacrine Hybrids as Potent Inhibitors of Human Cholinesterases Targeting Their Mid-gorge Recognition Sites 137
A Straightforward Approach for Engineering Efficacy and Selectivity at GPCRs 136
Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties 136
Specific Targeting of Peripheral Serotonin 5-HT3 Receptors. Synthesis, Biological Investigation and Structure Activity Relationships 136
Computational tool for fast in silico evaluation of hERG K+ channel affinity 135
Retinitis pigmentosa and retinal degenerations: deciphering pathways and targets for drug discovery and development 135
Broad inhibition of plasmodium falciparum cytoadherence by (+)-epigallocatechin gallate 133
Disease modifying anti-Alzheimer’s drugs: inhibitors of human cholinesterases interfering with β-amyloid aggregation 132
Site-directed mutagenesis of key residues unveiled a novel allosteric site on human adenosine kinase for Pyrrolobenzoxa(thia)zepinone non-nucleoside inhibitors 132
Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations 131
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-5 130
An efficient approach to chiral C8/C9-Piperazino-Substituted 1,4-Benzodiazepin-2-ones as peptidomimetic scaffolds 129
The Ca2+-ATPase (SERCA1) Is Inhibited by 4-Aminoquinoline Derivatives through Interference with Catalytic Activation by Ca2+, Whereas the ATPase E2 State Remains Functional 127
Screening and phenotypical characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) inhibitors as multistage antischistosomal agents 127
Rational design of the first difluorostatone-based PfSUB1 inhibitors 126
Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies 125
Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition 125
Identification of novel 3-Hydroxy-pyran-4-one derivatives as potent HIV-1 integrase inhibitors using in silico structure-based combinatorial library design approach 124
Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants 123
'Polycondensed heterocycles. Part 12: an approach to the synthesis of 2-acetyl-1'-methyl-1,2,3,4-tetrahydrospiro[isoquinoline-1,4'-pyrrolidine]-2'-one 123
Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands 121
Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies 121
Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells 121
Verbascoside Inhibits Promastigote Growth and Arginase Activity of Leishmania amazonensis 120
Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the ‘‘primer grip’’ region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants 120
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation and protein-ligand X-ray studies 118
In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitors 116
CONDENSED PYRIMIDINONES ACTIVE ON GLUTAMATERGIC RECEPTORS 116
NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS 116
Autophagy modulators for the treatment of oral and esophageal squamous cell carcinomas 114
Synthesis and Pharmacological Evaluation of Potent and Highly Selective D3 Receptor Ligands: Inhibition of Cocaine-Seeking Behaviour and the Role of Dopamine D3/D2Receptors 113
Totale 16.418
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.932
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.572 0 0 0 0 293 390 376 452 326 374 113 248
2020/20213.638 146 285 128 317 263 586 299 439 300 416 287 172
2021/20222.322 197 269 210 144 101 55 124 100 112 265 273 472
2022/20232.888 167 271 398 364 314 558 82 228 272 100 83 51
2023/20242.789 100 52 253 126 171 740 852 41 28 87 113 226
2024/20251.356 139 212 610 269 126 0 0 0 0 0 0 0
Totale 20.758